NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals logo
$14.70 -0.19 (-1.28%)
Closing price 03:59 PM Eastern
Extended Trading
$14.76 +0.06 (+0.39%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Advanced

Key Stats

Today's Range
$14.63
▼
$14.97
50-Day Range
$14.70
▼
$17.36
52-Week Range
$13.52
▼
$19.25
Volume
1.34 million shs
Average Volume
922,061 shs
Market Capitalization
$1.97 billion
P/E Ratio
15.18
Dividend Yield
N/A
Price Target
$17.33
Consensus Rating
Moderate Buy

Company Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs.

Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy.

Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis. Its activities have included the development and commercialization of Lupkynis, with a focus on serving patients in the United States and other markets where the medicine is authorized.

AI Generated. May Contain Errors.

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

AUPH MarketRank™: 
3.2524137931 of 5 stars

Aurinia Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 234th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    Aurinia Pharmaceuticals has a consensus price target of $17.33, representing about 17.9% upside from its current price of $14.70.

  • Amount of Analyst Coverage

    Aurinia Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Aurinia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurinia Pharmaceuticals are expected to grow by 7.22% in the coming year, from $0.97 to $1.04 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurinia Pharmaceuticals is 15.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.30.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurinia Pharmaceuticals is 15.18, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.47.

  • Price to Book Value per Share Ratio

    Aurinia Pharmaceuticals has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.94% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 10.31, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 8.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aurinia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aurinia Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Aurinia Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

  • Read more about Aurinia Pharmaceuticals' insider trading history.
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AUPH Stock News Headlines

Aurinia Pharmaceuticals (AUPH) AI Stock Analysis
Aurinia: Paying For Growth That Is Already Fading
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
Aurinia Skids on Results
See More Headlines

AUPH Stock Analysis - Frequently Asked Questions

Aurinia Pharmaceuticals' stock was trading at $15.95 at the start of the year. Since then, AUPH shares have decreased by 7.8% and is now trading at $14.6990.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its quarterly earnings data on Friday, October, 30th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.01. The biotechnology company had revenue of $83.70 million for the quarter, compared to analysts' expectations of $83.61 million. Aurinia Pharmaceuticals had a net margin of 97.68% and a trailing twelve-month return on equity of 22.99%.

Top institutional investors of Aurinia Pharmaceuticals include Goldman Sachs Group Inc. (4.73%), State Street Corp (1.93%), Marshall Wace LLP (1.42%) and Ritholtz Wealth Management (0.30%). Insiders that own company stock include Kevin Tang, Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Greg Keenan and Jeffrey Allen Bailey.
View institutional ownership trends
.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Palantir Technologies (PLTR), Tesla (TSLA), Exelixis (EXEL) and Block (XYZ).

Company Calendar

Last Earnings
10/30/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AUPH
CIK
1600620
Employees
128
Year Founded
2013

Price Target and Rating

High Price Target
$18.00
Low Price Target
$16.00
Potential Upside/Downside
+17.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.29
Trailing P/E Ratio
6.42
Forward P/E Ratio
14.13
P/E Growth
N/A
Net Income
$287.20 million
Net Margins
97.68%
Pretax Margin
51.94%
Return on Equity
22.99%
Return on Assets
17.99%

Debt

Debt-to-Equity Ratio
0.06
Current Ratio
6.12
Quick Ratio
5.67

Sales & Book Value

Annual Sales
$321.74 million
Price / Sales
6.12
Cash Flow
$0.98 per share
Price / Cash Flow
14.93
Book Value
$4.91 per share
Price / Book
2.99

Miscellaneous

Outstanding Shares
133,999,000
Free Float
120,063,000
Market Cap
$1.97 billion
Optionable
Optionable
Beta
1.40

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:AUPH) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners